午夜一级毛片-手机看片99-动漫人物桶机免费动漫app-日日摸日日碰夜夜97|www.zyjlr.com

TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Shanxi Province 59 pharmaceutical waste label pharmaceutical enterprise why meeting initiative annulus?
 
Author:中國銘鉉 企劃部  Release Time:2017-9-7 10:38:40  Number Browse:863
 
Medical network - on September 7th September 4, shanxi YaoXie centralized bid procurement center issued "about the cancellation of acetaminophen double hydrogen codeine pieces and 59 pharmaceutical product gauge online buying qualification notice, and drug firms offered to waste standard or revocation of the net purchase qualifications.

▍ drug firms why waste the initiative?

In the whole country, fujian, zhejiang, gansu, sichuan and other provinces have all experienced the situation of drug companies taking the initiative to cancel the bid or cancel the network. How can the company bear the pain? This seems counterintuitive.

The author, after consulting the drug companies, learned that the voluntary abolition of the bid was indeed a voluntary and reasonable cause.

1. The bid price is too low

When it comes to drug companies, it is easy to understand why drug prices. There are two kinds of situations:

The first is probably because the price is too low, and the drug companies make little or no money, preferring to give up.

Scrutinize the shanxi revocation net-suspended 59 species, there is 0.32 yuan a of penicillin sodium for injection, there is 2.34 yuan a heparin sodium injection, the clinical commonly used cheap life-saving drugs, had appeared different degree of a wide range of out of stock.

In the second case, it is related to the drug tendering in other provinces.

According to the drug companies, according to the bidding, the price of shanxi's many are among the lowest in the whole country, some varieties in order to avoid price linkage influence other provinces of the bid price, choose to give up the market in shanxi is also understandable.

Acetaminophen double hydrogen codeine tablets, for example, the prices are in 30 yuan, 20 yuan, and the price is only 14.4 yuan in shanxi, the price is in other parts of the linkage is one thing, and estimate the products in the future the bidding price and may be in the 14 yuan.

Now in the tender season, there is also a "killer" price linkage, it is understandable that some drug companies waive the market of price depressions, which is necessary. From the point of view of maintaining the price of the company, it is reasonable to give up some of the market and lose the car.

2. Unable to supply normal

Until then, a number of provinces had imposed penalties on companies that could not normally supply.

To cancel the bid, to cancel the qualification of the bid, to deduct the performance margin, to include the bad record, to cancel all products of the company in the province. It has even been kicked out of the provincial market for two years.

It is conceivable that if normal supply cannot be achieved, the cost to drug companies will be very high. The cost of raw materials, production line transformation, environmental improvement and other causes can cause the manufacturer to stop production, so it is easy to make regular deliveries without the contract. In the event that losses are minimised, many drug companies will opt out of the market.

As we can see, the current drug companies, which have been awarded the price at all costs, have turned to the bottom line. It is not clear how many drug companies will be proactively used in the future due to drug prices. But if this continues to develop, will there be drugs available in hospitals in the future?

 
Previous article:Shaanxi county, town, village, also need to implement consumables "two ticket system"!
Next article:Ningxia's "two-ticket" policy has a new change province, not a single vote!
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粵公網安備 44011202000029號